Navigation Links
Micromet Reports Interim Data from Phase 1 Study of BiTE Antibody MT110 for the Treatment of Solid Tumors
Date:9/21/2009

BETHESDA, Md., Sept. 21 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented first interim data from a phase 1 dose-escalation clinical study for BiTE antibody MT110, the first T-cell engaging antibody for the treatment of solid tumors. The interim data(1) were presented at the Multidisciplinary Congress of the European Cancer Organisation (ECCO) and 34th meeting of the European Society for Medical Oncology (ESMO) in Berlin, Germany. MT110 is designed to direct the patients' own T cells against cancer cells that express the epithelial cell adhesion molecule (EpCAM).

To date, 20 patients with late-stage lung or gastrointestinal cancers have been treated with MT110. The starting dose in this phase 1 dose escalation trial was 1 g per patient per day. Results from doses up to 12 g per patient per day were reported. MT110 is administered by continuous intravenous infusion for a minimum of four weeks with the option of additional treatment cycles until disease progression. No maximum tolerated dose has been reached and dose escalation is ongoing. MT110 is well tolerated with no grade 3 or 4 clinical events related to MT110 therapy observed so far. The most frequent adverse events related to MT110 treatment were mild pyrexia and fatigue. Laboratory analysis of all patients revealed an early clinically asymptomatic increase of liver enzymes that normalized after several days under continued treatment. Other laboratory abnormalities included transient lymphopenia. No cytokine release syndrome, pancreatitis or immune response to MT110 was observed. At the dose levels tested to date, disease stabilization was seen in 7 of 18 evaluable patients aft
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... October 27, 2014 The “Molecular ... Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End ... Service, Software) - Global Forecast to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:10/27/2014)... Orlando, Florida (PRWEB) October 27, 2014 ... aims at reducing and eliminating several types of ... have not been achieved in over 30 years ... of Noah's Light Foundation, proves that one mom's ... was diagnosed just before Halloween trick-or-treating, and it’s ...
(Date:10/27/2014)... , Oct. 27, 2014 Pressure BioSciences, ... worldwide leader in the development and sale of ... sciences research market, today announced that Professor ... novel, accurate, highly reproducible, and robust method to ... high-throughput protein analysis on small needle biopsy samples ...
(Date:10/27/2014)... 27, 2014 Investor-Edge has initiated ... NBIX ), Insmed Inc. (NASDAQ: ... ), Dyax Corporation (NASDAQ: DYAX ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,483.72, up 0.69%, the Dow Jones Industrial ...
Breaking Biology Technology:Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... 24 The Pittsburgh Life Sciences,Greenhouse (PLSG), ... industry on a fast track for growth, ... Innovention Technologies, LLC, a developmental-stage,medical device company, ... a,highly-maneuverable surgical probe that will alleviate the ...
... The Interstate,Alliance for Stem Cell Research should adopt a ... the Foundation for Taxpayer and,Consumer Rights (FTCR) said today., ... state,stem cell programs, is meeting today and Thursday at ... still in its early stages, it is critical to ...
... Calif., Oct. 24 Immunosyn,Corporation,s (OTC Bulletin Board: ... brokers and financial institutions at the Financial,Services Exchange ... in Phoenix, AZ on Thursday, October 25, 2007. ... and,distribution rights to SF-1019 from its largest shareholder, ...
Cached Biology Technology:The PLSG Invests $115,000 in Innovention Technologies, LLC 2Consumers Call On Interstate Stem Cell Group To Endorse Open Meetings 2Immunosyn Corporation to Present at FSX 2
(Date:10/30/2014)... news release is available in German . ... as individuals prompt our fellow humans to behave socially? ... social dilemmas in game theory. Previous studies assumed that ... groups. Nonetheless, scientists from the Max Planck Institute for ... can exert an influence on the cooperative behaviour of ...
(Date:10/30/2014)... Philadelphia, PA, October 30, 2014 – Bacteria in ... are critical for digestion. Yet, these same bacteria ... system if they penetrate the gut and enter ... natural response to protect the body, chronic or ... diseases. Prior research has established the involvement of ...
(Date:10/30/2014)... Heidelberg, 30 October 2014 Biological membranes are mainly ... of adsorption of solution ions onto lipid membranes ... a new study provides a quantitative description of ... ions. Joanna Kotyńska and Zbigniew Figaszewski from the ... a study describing these findings, just published in ...
Breaking Biology News(10 mins):Together we are strong -- or insufferable 2Together we are strong -- or insufferable 3Together we are strong -- or insufferable 4Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2Ion adsorption matter in biology 2
... result of natural processes that exploited early Earth,s raw ... to minerals for such essential tasks as the synthesis ... metabolic energy. But this assumes that the mineral species ... they were during Earth,s first 550 million yearsthe Hadean ...
... size increases, so do portion size and the amount of ... how susceptible people are to this plate-size bias? New research ... and introverted children respond differently to environmental cues, such as ... examined the breakfast behaviors of kids, ages 6 to 10, ...
... discovery may help explain the surprisingly strong connections between ... Sleep loss increases the risk of Alzheimer,s ... signs of this devastating disorder. Scientists at Washington ... University of Pennsylvania have shown that brain cell damage ...
Cached Biology News:Ancient minerals: Which gave rise to life? 2Extrovert and introvert children are not equally influenced by plate size 2Broken cellular 'clock' linked to brain damage 2Broken cellular 'clock' linked to brain damage 3
... Ciphergen's ProteinChip arrays have been ... from biological samples. A variety of ... of proteins according to their unique ... different spots, allowing side-by-side sample comparison, ...
... Assay with SR-101 Labeled Substrates (red ... Accurately measure serine protease activation • ... B-Bridge's FLISP Kits utilize cell-permeable, fluorescently ... to measure chymotrypsin-like activity in whole ...
... Leu-CMK FLISP Assay with FAM-Labeled Substrate ... • Accurately measure serine protease activation ... • B-Bridge's FLISP Kits utilize cell-permeable, ... (FLISPs) to measure chymotrypsin-like activity in ...
... instrument is the cycler that revolutionized ... uniformity and swappable blocks ensure consistent ... This rugged machine is more than ... for new features and upgrades as ...
Biology Products: